Sonoma Pharmaceuticals, Inc.
SNOA
$1.33
$0.010.38%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 15.20% | 27.87% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 15.20% | 27.87% | |||
| Cost of Revenue | 13.28% | 25.23% | |||
| Gross Profit | 18.16% | 32.18% | |||
| SG&A Expenses | 1.66% | 12.20% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.03% | 17.60% | |||
| Operating Income | 88.60% | 48.23% | |||
| Income Before Tax | 33.60% | 47.63% | |||
| Income Tax Expenses | -- | 164.62% | |||
| Earnings from Continuing Operations | 43.20% | 29.06% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 43.20% | 29.06% | |||
| EBIT | 88.60% | 48.23% | |||
| EBITDA | 97.48% | 50.62% | |||
| EPS Basic | 74.38% | 29.95% | |||
| Normalized Basic EPS | 70.06% | 48.30% | |||
| EPS Diluted | 74.38% | 29.95% | |||
| Normalized Diluted EPS | 70.06% | 48.30% | |||
| Average Basic Shares Outstanding | 121.67% | 1.28% | |||
| Average Diluted Shares Outstanding | 121.67% | 1.28% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||